GVGabriela Abigail Ortega Villacreses

Gabriela Abigail Ortega Villacreses

*This is an algorithmically generated author record based on publicly available information.

Gabriela Abigail Ortega Villacreses has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    REVISIÓN BIBLIOGRÁFICA: Abordaje de las convulsiones en pediatría: criterios para el tratamiento farmacológico inmediato, la vigilancia clínica y la observación hospitalaria

    by Silvia Carolina Villacres Gavilanes, Jacqueline Estefanía Alarcón Herrera, Lissette Alejandra Tisalema Laura, Gabriela Abigail Ortega Villacreses, María Paula Villagomez Mayorga

    Introduction: Seizures are among the most common neurological emergencies in childhood. Accurately determining which patients require long-term antiseizure medication (ASM) therapy and which may be managed exclusively through clinical observation remains a significant clinical challenge. Objective: To analyze and standardize the clinical, electroencephalographic, and neuroimaging criteria used to distinguish pediatric patients with seizures who require pharmacological treatment from those who may be managed through observation. Methods: A systematic exploratory search was conducted in indexed databases, including PubMed, ScienceDirect, SciELO, and the Cochrane Library, using DeCS/MeSH terms. Clinical practice guidelines, meta-analyses, and clinical trials published between 2021 and 2026 were selected. Results: The available evidence indicates that a first unprovoked seizure is associated with a recurrence risk of approximately 40–50%; therefore, close clinical observation is generally the preferred management strategy. Long-term pharmacological treatment is indicated when the estimated risk of recurrence exceeds 60%, particularly in the presence of clear epileptiform discharges on electroencephalography, an abnormal baseline neurological examination, structural abnormalities on neuroimaging, or status epilepticus at presentation. Conclusion: In pediatric patients, the decision to initiate antiseizure therapy should not be determined by the dramatic clinical appearance of the first seizure. Instead, it should be based on an objective assessment of recurrence risk and a careful evaluation of the benefit–risk profile of antiseizure medications (American Academy of Pediatrics, 2022; Berg et al., 2022; National Institute for Health and Care Excellence, 2022).

  • CARACTERIZACIÓN Y EPIDEMIOLOGÍA DE LAS INFECCIONES PARASITARIAS DE LA PIEL. UN ANÁLISIS COMPLETO DE LA PREVALENCIA, LOS FACTORES DE RIESGO Y LAS OPCIONES DE TRATAMIENTO

    by Palacios Calderón Geanella Amada, Quezada Terán Steven René, Lema Carrera Mirian Ernestina, Morales Domínguez Natalia Isabel, Chamorro Barona Angelica Estefania, Ortega Villacreses Gabriela Abigail, Medina Cobo Myriam Raquel

    Nº de DOI: 10.34896/RSI.2024.45.22.001 AUTORES Geanella Amada Palacios Calderón. Médico General. Adscrita del Hospital General Docente de Calderón. Investigadora Independiente del Departamento de Docencia e Investigación Matilde Hidalgo de Procel. Egresada de la Universidad Católica de Santiago de Guayaquil. (Quito-Ecuador). https://orcid.org/0009-0004-5865-2789 Steven René Quezada Terán. Médico General. Adscrito a Clínicas […]